ADC Therapeutics
ADCT
77 hedge funds and large institutions have $173M invested in ADC Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 10 reducing their positions, and 14 closing their positions.
240% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 10
141% more call options, than puts
Call options by funds: $265K | Put options by funds: $110K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
6% more capital invested
Capital invested by funds: $164M → $173M (+$9.19M)
4% more funds holding
Funds holding: 74 → 77 (+3)
2.91% more ownership
Funds ownership: 53.85% → 56.76% (+2.9%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.04M |
| 2 |
BlackRock
New York
|
+$2.66M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.44M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$1.26M |
| 5 |
O
OrbiMed
New York
|
+$684K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.22M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.52M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$1.5M |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$1.02M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$605K |
ADCT Hedge Fund Activity: Q3 2024 in Review
77 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2024, worth a combined $173M — up 5.6% from $164M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ADCT positions and 14 closed out — a net gain of 4 holders — while 34 added to existing stakes and 10 trimmed.
The largest buyer was Bank of America, adding an estimated $4.04M. The largest seller was Artal Group, exiting entirely with an estimated $3.22M sold.
- 77 institutional investors held ADC Therapeutics (ADCT) as of Q3 2024, up from 74 in Q2 2024.
- Funds reported $173M of ADC Therapeutics stock for Q3 2024, up 5.6% quarter-over-quarter.
- 18 funds opened new ADC Therapeutics positions in Q3 2024 and 14 closed out, a net change of +4 holders.
- The largest ADC Therapeutics buyer in Q3 2024 was Bank of America, an estimated $4.04M added.
- The largest ADC Therapeutics seller in Q3 2024 was Artal Group, an estimated $3.22M sold.
Based on aggregated 13F filings for Q3 2024.